推薦產品
一般說明
The MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Tranduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 uL at 1 x 106 TU/mL via p24 assay.
当使用MISSION® TRC shRNA克隆进行实验时，选择适当对照品是您的实验设计的关键要素，以便准确解释敲低结果。 MISSION对照转导颗粒是监测转导效率的关键阳性对照。
想要查看更多应用数据、实验方案和载体图谱，请访问 sigma.com/shrna。
想要查看更多应用数据、实验方案和载体图谱，请访问 sigma.com/shrna。
應用
To see more application data, protocols, vector maps visit sigma.com/shrna.
法律資訊
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
Manier S
Leukemia, 31(4), 853-860 (2017)
STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.
Pedroza M
Faseb Journal, 30(1), 129-140 (2016)
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
Lewis KM
Lung Cancer, 90(2), 182-190 (2015)
Curtis A Clark et al.
Cancer research, 76(23), 6964-6974 (2016-09-28)
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its
Katherine M Lewis et al.
Lung cancer (Amsterdam, Netherlands), 90(2), 182-190 (2015-09-28)
Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) has an overall 5-year survival rate of 15%. While aberrant STAT3 activation has previously been observed in NSCLC, the scope of
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務